Sanara Medtech (SMTI) Stock Price

Sanara Medtech Price

NASDAQ·CLOSED
34.15USD-0.0100 (-0.03 %)
Market closed

Revenue has compounded at 39.3% per year over the past 19 years to 103.12 M USD. Sanara Medtech's net margin stands at -36.4%, down from -32.8% several years earlier. Analysts set a median price target of 40.80 USD, implying 19.5% above the current price. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 109% above its 52-week low.

Sanara Medtech stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sanara Medtech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sanara Medtech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sanara Medtech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sanara Medtech Stock Price History
DateSanara Medtech Price
8/14/202634.15 USD
8/13/202634.16 USD
8/12/202634.33 USD
8/11/202634.38 USD
8/10/202634.25 USD
8/7/202634.10 USD
8/6/202634.09 USD
8/5/202634.10 USD
8/4/202634.08 USD
8/3/202634.00 USD
7/31/202633.86 USD
7/30/202634.06 USD
7/29/202627.52 USD
7/27/202625.93 USD
7/23/202625.50 USD
7/22/202625.54 USD
7/21/202625.50 USD
7/20/202625.00 USD
7/17/202625.00 USD
7/16/202625.32 USD
7/15/202624.53 USD
7/14/202623.45 USD
7/13/202624.55 USD
7/10/202623.82 USD
7/9/202623.88 USD
7/8/202624.02 USD
7/7/202624.79 USD
7/6/202624.76 USD
7/2/202624.84 USD
7/1/202624.27 USD
6/30/202623.59 USD
6/29/202624.58 USD
6/26/202623.88 USD
6/25/202623.12 USD
6/24/202622.89 USD
6/23/202621.75 USD
6/22/202621.44 USD
6/18/202622.02 USD
6/17/202621.22 USD
6/16/202622.69 USD
6/15/202621.89 USD
6/12/202620.81 USD
6/11/202621.50 USD
6/10/202622.81 USD
6/9/202622.72 USD
6/8/202622.09 USD
6/5/202622.44 USD
6/4/202622.12 USD
6/3/202620.97 USD
6/2/202621.26 USD
6/1/202621.92 USD
5/29/202622.79 USD
5/28/202623.79 USD
5/27/202623.38 USD
5/26/202622.93 USD
5/22/202623.17 USD
5/21/202623.64 USD
5/20/202623.00 USD
5/19/202622.72 USD
5/18/202621.89 USD
5/15/202621.06 USD
5/14/202621.64 USD
5/13/202621.10 USD
5/12/202620.44 USD
5/11/202618.02 USD
5/8/202618.40 USD
5/7/202619.08 USD
5/6/202619.15 USD
5/5/202619.62 USD
5/4/202618.99 USD
5/1/202619.73 USD
4/30/202618.99 USD
4/29/202618.20 USD
4/28/202618.70 USD
4/27/202618.93 USD
4/24/202619.22 USD
4/23/202619.57 USD
4/22/202619.96 USD
4/21/202619.80 USD
4/20/202620.62 USD
4/17/202620.77 USD
4/16/202619.78 USD
4/15/202620.01 USD
4/14/202618.51 USD
4/13/202617.60 USD
4/10/202616.53 USD
4/9/202616.97 USD
4/8/202617.00 USD
4/7/202616.83 USD
4/6/202617.19 USD
4/2/202617.24 USD
4/1/202617.25 USD
3/31/202617.18 USD
3/30/202617.29 USD
3/27/202616.96 USD
3/26/202618.01 USD
3/25/202616.34 USD
3/24/202618.08 USD
3/23/202618.34 USD
3/20/202618.38 USD
3/19/202618.72 USD
3/18/202618.66 USD
3/17/202619.62 USD
3/16/202619.64 USD
3/13/202619.48 USD
3/12/202619.09 USD
3/11/202619.60 USD
3/10/202619.69 USD
3/9/202620.74 USD
3/6/202618.87 USD
3/5/202619.20 USD
3/4/202620.09 USD
3/3/202620.84 USD
3/2/202620.48 USD
2/27/202620.44 USD
2/26/202621.07 USD
2/25/202619.90 USD
2/24/202619.92 USD
2/23/202620.72 USD
2/20/202620.45 USD
2/19/202619.94 USD
2/18/202619.65 USD
2/17/202619.09 USD
2/13/202618.91 USD
2/12/202619.43 USD
2/11/202619.52 USD
2/10/202619.52 USD
2/9/202619.92 USD
2/6/202620.24 USD
2/5/202620.04 USD
2/4/202620.74 USD
2/3/202620.55 USD
2/2/202622.05 USD
1/30/202622.00 USD
1/29/202621.06 USD
1/28/202621.38 USD
1/27/202620.80 USD
1/26/202621.25 USD
1/23/202621.75 USD
1/22/202622.25 USD
1/21/202622.79 USD
1/20/202621.77 USD
1/16/202622.84 USD
1/15/202623.77 USD
1/14/202623.15 USD
1/13/202623.66 USD
1/12/202623.97 USD
1/9/202624.35 USD
1/8/202625.07 USD
1/7/202624.39 USD
1/6/202624.88 USD
1/5/202623.56 USD
1/2/202623.10 USD
12/31/202523.35 USD
12/30/202523.87 USD
12/29/202524.25 USD
12/26/202524.22 USD
12/24/202524.52 USD
12/23/202524.51 USD
12/22/202525.04 USD
12/19/202524.21 USD
12/18/202524.14 USD
12/17/202524.44 USD
12/16/202525.20 USD
12/15/202524.70 USD
12/12/202525.91 USD
12/11/202524.10 USD
12/10/202524.40 USD
12/9/202523.63 USD
12/8/202521.76 USD
12/5/202521.69 USD
12/4/202521.80 USD
12/3/202521.07 USD
12/2/202520.20 USD
12/1/202520.33 USD
11/28/202520.92 USD
11/26/202520.76 USD
11/25/202520.37 USD
11/24/202519.70 USD
11/21/202519.48 USD
11/20/202519.14 USD
11/19/202519.06 USD
11/18/202520.90 USD
11/17/202521.07 USD
11/14/202521.54 USD
11/13/202519.61 USD
11/12/202521.11 USD
11/11/202528.04 USD
11/10/202528.16 USD
11/7/202527.72 USD
11/6/202527.87 USD
11/5/202527.60 USD
11/4/202528.22 USD
11/3/202528.99 USD
10/31/202529.30 USD
10/30/202528.81 USD
10/29/202529.44 USD
10/28/202530.35 USD
10/27/202530.50 USD
10/24/202531.08 USD
10/23/202530.08 USD
10/22/202531.18 USD
10/21/202529.15 USD
10/20/202529.52 USD
10/17/202528.26 USD
10/16/202529.30 USD
10/15/202529.90 USD
10/14/202529.96 USD
10/13/202530.00 USD
10/10/202529.86 USD
10/9/202531.61 USD
10/8/202532.33 USD
10/7/202530.33 USD
10/6/202531.26 USD
10/3/202531.19 USD
10/2/202530.88 USD
10/1/202530.80 USD
9/30/202531.73 USD
9/29/202531.84 USD
9/26/202531.85 USD
9/25/202531.24 USD
9/24/202532.57 USD
9/23/202533.10 USD
9/22/202533.83 USD
9/19/202532.89 USD
9/18/202534.64 USD
9/17/202534.19 USD
9/16/202535.08 USD
9/15/202535.01 USD
9/12/202533.96 USD
9/11/202535.28 USD
9/10/202533.76 USD
9/9/202534.39 USD
9/8/202535.75 USD
9/5/202533.57 USD
9/4/202534.04 USD
9/3/202533.51 USD
9/2/202534.63 USD
8/29/202533.66 USD
8/28/202533.73 USD
8/27/202533.94 USD
8/26/202533.65 USD
8/25/202532.93 USD
8/22/202533.95 USD
8/21/202530.52 USD
8/20/202530.73 USD
8/19/202530.86 USD
8/18/202531.58 USD
Access this data via the Eulerpool API
Get Free API Key

Sanara Medtech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
64.99 M USD
-3.97 M USD
-4.30 M USD
Jan 1, 2024
86.67 M USD
-6.81 M USD
-9.66 M USD
Jan 1, 2025
103.12 M USD
9.15 M USD
-37.56 M USD
Jan 1, 2026 (e)
117.00 M USD
46.64 M USD
1.56 M USD
Jan 1, 2027 (e)
133.00 M USD
53.01 M USD
4.16 M USD
Jan 1, 2028 (e)
152.00 M USD
60.59 M USD
5.72 M USD
Jan 1, 2029 (e)
170.00 M USD
67.76 M USD
8.14 M USD
Jan 1, 2030 (e)
189.00 M USD
75.33 M USD
9.39 M USD

Sanara Medtech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 16, 2026, 2:25 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
3.005.006.005.0011.0015.0024.0045.0064.0086.00103.00117.00133.00152.00170.00189.00
50.0066.6720.00-16.67120.0036.3660.0087.5042.2234.3819.7713.5913.6814.2911.8411.18
66.6780.0083.33100.0090.9186.6787.5086.6789.0690.7089.3289.3289.3289.3289.3289.32
2.004.005.005.0010.0013.0021.0039.0057.0078.0092.00104.50118.80135.77151.84168.82
––––-2.00-5.00-7.00-13.00-3.00-6.009.0046.0053.0060.0067.0075.00
––––-18.18-33.33-29.17-28.89-4.69-6.988.7439.3239.8539.4739.4139.68
-1.00–––-2.00-4.00-7.00-7.00-4.00-9.00-37.001.004.005.008.009.00
-50.00––––100.0075.00–-42.86125.00311.11-102.70300.0025.0060.0012.50
1.071.091.112.376.236.237.528.308.548.538.628.628.628.628.628.62
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sanara Medtech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sanara Medtech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sanara Medtech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sanara Medtech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sanara Medtech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sanara Medtech stock margins

The Sanara Medtech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sanara Medtech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sanara Medtech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
90.43 %
-33.11 %
-32.81 %
Jan 1, 2022
86.12 %
-29.78 %
-17.31 %
Jan 1, 2023
87.92 %
-6.10 %
-6.62 %
Jan 1, 2024
90.61 %
-7.85 %
-11.15 %
Jan 1, 2025
90.13 %
8.87 %
-36.43 %
Jan 1, 2026 (e)
90.13 %
39.86 %
1.34 %
Jan 1, 2027 (e)
90.13 %
39.86 %
3.13 %
Jan 1, 2028 (e)
90.13 %
39.86 %
3.76 %

Sanara Medtech Stock Revenue, EBIT, Earnings per Share

The Sanara Medtech earnings per share therefore indicates how much revenue Sanara Medtech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
3.21 USD
-1.06 USD
-1.05 USD
Jan 1, 2022
5.52 USD
-1.64 USD
-0.96 USD
Jan 1, 2023
7.61 USD
-0.46 USD
-0.50 USD
Jan 1, 2024
10.16 USD
-0.80 USD
-1.13 USD
Jan 1, 2025
11.96 USD
1.06 USD
-4.36 USD
Jan 1, 2026 (e)
13.09 USD
5.41 USD
0.18 USD
Jan 1, 2027 (e)
14.88 USD
6.15 USD
0.47 USD
Jan 1, 2028 (e)
17.00 USD
7.03 USD
0.64 USD

Sanara Medtech business model & stock analysis

Sanara Medtech Inc is a leading company specializing in the development of innovative medical devices and solutions. The company is headquartered in Texas, USA and has experienced significant growth since its founding in 2014. Its areas of specialization include wound care, incontinence management, and dermatology. The history of Sanara Medtech Inc began in 2014 when a team of experienced medical technology experts founded the company. Leveraging their extensive industry knowledge and expertise, the team quickly identified a market niche and established themselves as a leading provider of innovative solutions. The business model of Sanara Medtech Inc is focused on developing medical devices and solutions that aim to improve the daily lives of patients and healthcare professionals. The company is committed to developing and manufacturing top-quality products that contribute to enhancing patient care and supporting healthcare professionals in their tasks. Sanara Medtech Inc offers a wide range of products tailored to the needs of patients and medical professionals. Its wound care products include wound dressings, wound healing ointments, and other specialized products for treating chronic and acute wounds. The incontinence management products include disposable and reusable incontinence products designed to improve the lives of individuals with incontinence issues. Dermatology products encompass a wide range of products for treating skin conditions such as psoriasis, eczema, and rosacea, to name a few. Another focus of Sanara Medtech Inc is collaborating with private and public healthcare facilities to ensure the availability of its products in hospitals, clinics, nursing homes, and other healthcare facilities. The company also offers training and educational programs for healthcare professionals to ensure proper product use. In summary, Sanara Medtech Inc is an innovative company specializing in the development of medical devices and solutions tailored to the needs of patients and healthcare professionals. Its goal is to develop top-quality products that contribute to the improvement of healthcare and enhance the lives of patients. With a wide range of products and a strong market presence, Sanara Medtech Inc is a leading force in the medical technology industry.

Sanara Medtech SWOT Analysis

Strengths

Sanara Medtech Inc has a strong portfolio of innovative medical technologies and products, which gives them a competitive advantage in the market.

The company has a dedicated and experienced management team that possesses excellent expertise in the healthcare industry.

Sanara Medtech has established strong relationships with key stakeholders, including healthcare professionals, hospitals, and distributors, contributing to its market presence.

Weaknesses

The company's heavy reliance on a limited number of suppliers may expose Sanara Medtech to potential supply chain disruptions.

Sanara Medtech's current market share is relatively small compared to larger competitors, limiting its brand recognition and market reach.

The company lacks diversification in its product offerings and heavily depends on a few key products for revenue generation.

Opportunities

The growing demand for advanced wound care solutions presents significant growth opportunities for Sanara Medtech Inc.

Expansion into international markets can help Sanara Medtech to tap into new customer bases and diversify its revenue streams.

The increasing adoption of telemedicine and remote healthcare services provides an opportunity for the company to develop innovative virtual wound care solutions.

Threats

The healthcare industry is highly regulated, which poses compliance challenges for Sanara Medtech and exposes the company to legal and regulatory risks.

Intense competition from established medical technology companies and new entrants in the market may potentially erode Sanara Medtech's market share.

Economic downturns and changes in healthcare policies and reimbursement models can impact the purchasing power of healthcare providers, affecting the demand for Sanara Medtech's products.

Sanara Medtech Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Sanara Medtech Employees
Details
Date
Sanara Medtech Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Sanara Medtech Segments

Sanara Medtech Revenue by Segment (1/2)

  • Max

Soft Tissue Repair Products
Bone Fusion Products
Details
Date
Soft Tissue Repair Products
Product Sales Revenue
Bone Fusion Products
Royalty
Royalty Revenue
Jan 1, 2024
76.13 M USD
0.00 USD
10.55 M USD
0.00 USD
0.00 USD

Sanara Medtech Revenue by Segment (2/2)

  • Max

Sanara Surgical
Details
Date
Sanara Surgical
Jan 1, 2024
86.67 M USD

Sanara Medtech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sanara Medtech historical P/E ratio, EBIT multiple, and P/S ratio

Sanara Medtech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sanara Medtech shares outstanding

The number of shares of Sanara Medtech was 8.62 M in 2025. This indicates how many shares Sanara Medtech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
7.52 M Stocks
Jan 1, 2022
8.30 M Stocks
Jan 1, 2023
8.54 M Stocks
Jan 1, 2024
8.53 M Stocks
Jan 1, 2025
8.62 M Stocks
Jan 1, 2026 (e)
8.62 M Stocks
Jan 1, 2027 (e)
8.62 M Stocks
Jan 1, 2028 (e)
8.62 M Stocks

Sanara Medtech stock splits

In Sanara Medtech's history, there have been no stock splits.

Current Sanara Medtech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.44 %
Buy
87.50 % (7)
Hold
12.50 % (1)
Sell
0.00 % (0)
12M Price Target
40.80
Last Price
34.15
Currency
USD
12M Return Potential
19.47 %
LTM Return
0 %

Sanara Medtech Analyst Rating Actions

DateFirmActionRatingReliability
7/30/2026
HC Wainwright & Co.
HC Wainwright & Co.
DowngradeBuyNeutral–
1/26/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/14/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/18/2025
HC Wainwright& Co.
HC Wainwright& Co.
MaintainedBuy–
8/18/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/26/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/26/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44
1/23/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
1/23/2025
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedOverweight44

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Sanara Medtech Earnings Calls

2025

Sanara Medtech Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/17/2026-0.03USD-29.53 MUSD-2026 Q2
5/12/2026-0.13USD-27.34 MUSD-2026 Q1
3/24/20260.11USD-27.95 MUSD-2025 Q4
8/13/2025-0.45USD-25.65 MUSD-2025 Q2
11/12/2024-0.63USD-21.11 MUSD-2024 Q3
3/18/2024-0.13USD-16.83 MUSD-2023 Q4
3/28/2023-0.17USD-17.05 MUSD-2022 Q4
11/14/2022-0.33USD-14.92 MUSD-2022 Q3
8/15/2022-0.29USD-8.83 MUSD-2022 Q2
3/31/2022-0.28USD-6.19 MUSD-2021 Q4

EESG©

Eulerpool ESG Scorecard© for the Sanara Medtech stock

17/100
4
Environment
20
Social
27
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sanara Medtech shareholder structure

% Name
2.09282%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.96849%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.28167%
Stonebridge Wealth Management, LLC
Stonebridge Wealth Management, LLC
1.00504%
Yon (Seth D)
Yon (Seth D)
0.86956%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
0.79990%
Marshall Wace LLP
Marshall Wace LLP
...

Sanara Medtech Beneficial Ownership Filings (SEC 13D/G)

Free Float
34.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
32.15%
STUCKERT JAMES W
STUCKERT JAMES W
SEC ↗
26.37%
James W. Stuckert
James W. Stuckert
SEC ↗
13.47%
Howell S. Oden Jr.
Howell S. Oden Jr.
SEC ↗
9.99%
26-0147159
26-0147159
SEC ↗
8.90%
Utah Resources International, Inc.  (87-0273519)
Utah Resources International, Inc.  (87-0273519)
SEC ↗
8.90%
Tonaquint, Inc.  (87-0285597)
Tonaquint, Inc.  (87-0285597)
SEC ↗
8.90%
John M. Fife
John M. Fife
SEC ↗
8.90%
JFV Holdings, Inc.  (36-4426825)
JFV Holdings, Inc.  (36-4426825)
SEC ↗
8.90%
Inter-Mountain Capital I Corp.  (36-4075407)
Inter-Mountain Capital I Corp.  (36-4075407)
SEC ↗
6.70%
Ron Nixon
Ron Nixon
SEC ↗

Sanara Medtech Executives and Management Board

12 members · avg. age 58 · 25 % women

JW

Mr. Jacob Waldrop (43)

Chief Operating Officer

518,219.00 USD

Management

SY

Mr. Seth Yon (50)

President, Chief Executive Officer, Director · since 2025

–
ET

Ms. Elizabeth Taylor (49)

Chief Financial Officer

–
SM

Mr. Suresh Muppalla (55)

President and Chief Executive Officer of Tissue Health Plus, LLC

–

Board of Directors

RN

Mr. Ronald Nixon (69)

Executive Chairman of the Board · since 2019

855,758.00 USD
AS

Ms. Ann Salamone (74)

Director

269,912.00 USD
RD

Mr. Robert DeSutter (56)

Independent Director

122,954.00 USD
ET

Mr. Eric Tanzberger (56)

Independent Director

117,825.00 USD
RM

Mr. Roszell Mack (58)

Independent Director

112,697.00 USD
EM

Mr. Eric Major (55)

Independent Director

107,569.00 USD

Sanara Medtech Supply Chain

Frequently asked questions about Sanara Medtech

The business model of Sanara Medtech Inc focuses on developing and commercializing innovative biotechnology and medical device products. The company aims to provide advanced wound care solutions to cater to the growing needs of patients worldwide. Sanara Medtech Inc leverages its expertise in wound healing and tissue regeneration to develop cutting-edge products that enhance patient outcomes. By offering a diverse portfolio of advanced products, the company aims to address the unmet needs of healthcare professionals and improve the quality of life for patients. Sanara Medtech Inc continually strives to expand its market presence and deliver innovative solutions for wound healing and tissue repair.

Sanara Medtech Inc is primarily active in the medical technology industry.

The main competitors of Sanara Medtech Inc in the market include companies such as Acelity, Mölnlycke Health Care, and Smith & Nephew.

Sanara Medtech Inc, formerly known as Wound Management Technologies, is a Texas-based medical technology company. It specializes in developing and commercializing advanced wound care products. Established in 2014, Sanara Medtech focuses on delivering innovative solutions to address acute and chronic wounds. Their products include a range of advanced wound dressings, collagen-based dressings, and therapeutic lotions designed to promote healing and improve patient outcomes. With a dedicated team of experts and strong research and development capabilities, Sanara Medtech is committed to providing effective and reliable wound care solutions to patients and healthcare providers worldwide.

Sanara Medtech Inc has achieved several significant milestones. The company successfully developed and commercialized its flagship product, the BIAKŌS® Antimicrobial Barrier Film, which provides advanced wound care solutions. Sanara Medtech Inc also received FDA 510(k) clearance for its BIAKŌS® Wound Gel, expanding its product portfolio. Additionally, the company formed strategic partnerships with healthcare providers and established distribution agreements to enhance market reach. Sanara Medtech Inc's dedication to innovation, regulatory compliance, and customer satisfaction has solidified its position as a leader in the medical technology industry.

Sanara Medtech Inc is primarily present in the United States.

Sanara Medtech Inc is a reputable company known for its strong values and corporate philosophy. With a customer-centric approach, they prioritize innovation, excellence, and integrity in all their operations. Sanara Medtech Inc aims to provide cutting-edge medical technologies and solutions that improve patient outcomes and quality of life. Backed by a highly skilled team and state-of-the-art research, they strive to deliver superior healthcare products and services. By fostering partnerships and collaboration, Sanara Medtech Inc demonstrates a commitment to advancing medical advancements and driving positive change in the industry. Their dedication to promoting excellence and integrity sets them apart as a leader in the healthcare sector.

Analysts currently set an average price target of 40.80 USD for the Sanara Medtech stock (median: 40.80 USD), implying +19.5 % versus the latest price. The consensus is based on 8 analyst ratings.

Sanara Medtech Analyst Price Targets 2026

8 analysts currently rate the Sanara Medtech stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Sanara Medtech to generate revenue of 117.00 M USD and earnings per share of 0.18 USD.

Sanara Medtech Analyst Price Targets 2026

Converted at the current exchange rate, the Sanara Medtech share trades at 29.53 EUR (34.15 USD).

The Sanara Medtech share (SMTI) is listed on 1 stock exchanges, including: NASDAQ (SMTI).

Sanara Medtech Inc. is a leading company in the field of wound care and offers innovative products and solutions for wound healing. The company is headquartered in Dallas, Texas and was founded in 2014. It specializes in providing patients and medical professionals with new products and technologies with clinically proven results. Sanara Medtech operates in three main areas: wound healing, incontinence and hygiene products, and hernia care. In the field of wound healing, the company offers a range of products specifically designed to accelerate and improve wound healing. This is achieved through the use of innovative dressing systems that regulate moisture, temperature, and oxygen levels to achieve optimal healing outcomes. In the incontinence and hygiene products sector, Sanara Medtech provides bladder and bowel incontinence management. Special absorbent pads and underpads are provided that are suitable for both men and women. The company also offers effective and skin-friendly cleansing lotions and cleaning products. In the hernia care sector, the company offers various implants and meshes. These include both new developments and standard products used for the stabilization of abdominal wall hernias. The products are surgical instruments and medical devices manufactured to the highest quality standards to achieve the best possible benefit for patients. Sanara Medtech's business model is focused on the healthcare market and aims to provide the best customer service and products in the field of wound care and medical devices. To achieve this, the company works closely with medical professionals and patient organizations. Sanara Medtech is committed to continuously improving existing products and offering innovative solutions in wound care to provide the best possible benefit for patients. Innovation, quality, and customer service are the key elements of Sanara Medtech's business model. The company relies on effective organization and coordination of all business areas, from research and development to sales. Sanara Medtech also aims to ensure sustainable economic growth through appropriate measures. In summary, Sanara Medtech Inc. is a company operating in the fields of wound healing, incontinence and hygiene products, and hernia care. The company offers innovative products and solutions of the highest quality standard and is committed to achieving the best possible benefit for patients through continuous research and development. The close partnerships with medical professionals and patient organizations enable the company to develop innovative products and provide the best possible customer service.

The expected revenue of Sanara Medtech is 117.00 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sanara Medtech is 1.56 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sanara Medtech is currently 188.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sanara Medtech stock.

The price-to-sales ratio (P/S) of Sanara Medtech is currently 2.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sanara Medtech stock.

The Eulerpool Quality Score for Sanara Medtech is 5/10.

The ISIN of Sanara Medtech is US79957L1008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sanara Medtech is SMTI. The ticker symbol is used to trade Sanara Medtech shares on the stock exchange.

Sanara Medtech paid dividends every year for the past 0 years.

Sanara Medtech is assigned to the 'Health' sector.

The dividends of Sanara Medtech are distributed in USD.

All fundamentals and in-depth analysis of Sanara Medtech

Our stock analysis for Sanara Medtech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sanara Medtech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sanara Medtech Stock
Sanara Medtech Revenue→
Sanara Medtech Stock
Sanara Medtech Net Income→
Sanara Medtech Stock
Sanara Medtech P/E→
Sanara Medtech Stock
Sanara Medtech P/S→
Sanara Medtech Stock
Sanara Medtech EBIT→
Sanara Medtech Stock
Sanara Medtech Dividend→
Sanara Medtech Stock
Sanara Medtech Directors Dealings→
Sanara Medtech Stock
Sanara Medtech Stocks→
Sanara Medtech Stock
Sanara Medtech Market capitalization→
Sanara Medtech Stock
Sanara Medtech Debt→
Sanara Medtech Stock
Sanara Medtech Liabilities→
Sanara Medtech Stock
Sanara Medtech Equity→
Sanara Medtech Stock
Sanara Medtech AAQS→
Sanara Medtech Stock
Sanara Medtech Employees→
Sanara Medtech Stock
Sanara Medtech ROE→
Sanara Medtech Stock
Sanara Medtech ROA→
Sanara Medtech Stock
Sanara Medtech ROCE→
Sanara Medtech Stock
Sanara Medtech News→
Sanara Medtech Stock
Sanara Medtech Analyst Price Targets→

Health Stocks

SanBio CoSanai Health Industry Group CoSanbo Hospital Management GroupSana BiotechnologySangamo TherapeuticsSamsung Pharm CoSangani HospitalsSamsung Biologics CoSanigen CoSamsrita LabsSanionaSamjin Pharmaceutical CoAll Stocks A–Z →